2022
DOI: 10.2468/jbes.73.150
|View full text |Cite
|
Sign up to set email alerts
|

進行/再発非小細胞肺癌における癌免疫療法治療効果と宿主免疫栄養状態との関連性の検討

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
15
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(17 citation statements)
references
References 0 publications
2
15
0
Order By: Relevance
“…Moreover, the comparison of AUC values revealed that the PNI had higher discriminative ability than did the NLR and PLR. Our results are supported by the results of other studies that have reported that the PNI is a more robust biomarker and exhibits higher internal and external validity in predicting survival when compared with other inflammationrelated prognostic indices, such as the NLR, PLR and CRP (Bruixola et al, 2018;Du et al, 2015;Shoji et al, 2019;Tokunaga et al, 2017).…”
Section: Discussionsupporting
confidence: 89%
See 1 more Smart Citation
“…Moreover, the comparison of AUC values revealed that the PNI had higher discriminative ability than did the NLR and PLR. Our results are supported by the results of other studies that have reported that the PNI is a more robust biomarker and exhibits higher internal and external validity in predicting survival when compared with other inflammationrelated prognostic indices, such as the NLR, PLR and CRP (Bruixola et al, 2018;Du et al, 2015;Shoji et al, 2019;Tokunaga et al, 2017).…”
Section: Discussionsupporting
confidence: 89%
“…Moreover, the comparison of AUC values revealed that the PNI had higher discriminative ability than did the NLR and PLR. Our results are supported by the results of other studies that have reported that the PNI is a more robust biomarker and exhibits higher internal and external validity in predicting survival when compared with other inflammation‐related prognostic indices, such as the NLR, PLR and CRP (Bruixola et al., 2018; Du et al., 2015; Shoji et al., 2019; Tokunaga et al., 2017). A partial explanation for these findings is that the PNI combines both nutritional status and systemic inflammatory response, thus possibly rendering it a superior prognostic indicator to other inflammation‐based indices, which reflect only the host's inflammatory components and may be strongly influenced by external factors such as intercurrent inflammation, infection and corticosteroid use.…”
Section: Discussionsupporting
confidence: 88%
“…It was found that there has a significant difference between elevated PLR and NLR levels with shorter OS and PFS in patients with advanced NSCLC treated with nivolumab (46). Pretreatment PNI has also been found to be an independent predictive biomarker for NSCLC patients after treatment with immune checkpoint inhibitors and may help to identify which patients can obtain good therapeutic effect from immune checkpoint inhibitors (47) there is no similar study on PNETs, immunotherapy is gradually emerging in SCLC research. It was found that acetazolamide monoclonal antibody could improve OS and PFS of SCLC patients more effectively than chemotherapy alone (48).…”
Section: Discussionmentioning
confidence: 99%
“…Another research compared the PNI before and after the operation and confirmed the effectiveness of preoperative PNI in the prognosis prediction of patients after anticancer drug therapy [26]. It can also be used as a biomarker to predict therapeutic efficacy, even in immune checkpoint inhibitor (ICI) monotherapy [27].…”
Section: Introductionmentioning
confidence: 85%